agilon health, inc. (AGL) Form 10-Q — Nov 4, 2026
agilon health delivered a dramatic financial turnaround in Q3 2026, posting net income of $34.9 million versus a $110.2 million net loss in the year-ago quarter, on total revenue of $1.52 billion (up 6%). The medical services expense ratio improved to 88.5% from 104.0%, driving Q3 Adjusted EBITDA of $64 million versus negative $91 million a year earlier. Nine-month results show the same inflection: net income of $102 million versus a $202 million loss in 2025, with operating cash flow swinging positive to $16.3 million from negative $85.2 million.
Key figures
- Eps
- 2.08
- Revenue
- 1519486000
- Net Income
- 34912000
- Total Assets
- 1565521000
- Cash Position
- 246379000
- Shares Outstanding
- 16795774
- Ma members
- 453600
- Mser q3 2025
- 104.0%
- Mser q3 2026
- 88.5%
- Q3 2025 revenue
- 1435321000
- Nine month revenue
- 4434689000
- Q3 adjusted ebitda
- 63684000
- Reverse split ratio
- 1:25
- Ma member change yoy
- -10%
- Marketable securities
- 65361000
- Nine month net income
- 101784000
- Nine month adjusted ebitda
- 187094000
- Operating cash flow nine months
- 16303000
- Cms aco attributed beneficiaries
- 112300
- Pmpm capitation rate increase q3
- 11%
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.